Nexalin Technology, Inc. develops non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology for brain-health and mental-health indications. Company news centers on clinical evidence for its neurostimulation platform, including peer-reviewed studies involving insomnia, depression-related symptoms, traumatic brain injury, PTSD, Alzheimer’s disease, dementia-related cognitive decline and ADHD.
Updates also cover the HALO™ Clarity headset, the NeuroCare® virtual clinic platform, collaborations with clinical research and academic organizations, FDA De Novo strategy, international regulatory activity, and public-company events affecting Nexalin securities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) provided a business update on March 27, 2023, highlighting progress in clinical trials for new neurostimulation devices aimed at treating mental health disorders. The Gen-2 and Gen-3 devices are expected to improve treatment efficacy without medication. Revenue for 2022 reached $1.3 million, a significant increase from $0.1 million in 2021, primarily due to more device sales. While operating expenses decreased to $2.8 million from $6.1 million, the net loss narrowed to $1.7 million per share. The company reports having $7.0 million in liquidity for future operations.